With a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now.

The average one-year price target for Recursion Pharmaceuticals (NasdaqGS:RXRX) has been revised to $6.12 / share. This is a decrease of 10.64% from the prior estimate of $6.85 dated April 25, 2026.

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

Three companies in particular sit right at the center of that transition: Tempus AI ( TEM 7.53%), Recursion Pharmaceuticals ( ...

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Earlier this year, Recursion Pharmaceuticals Inc RXRX initiated discussions with the FDA for the design of a registrational ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...